LifeSpan Biosciences acquired by Thompson Street Capital Partners

Thompson Street Capital Partners, a private equity firm based in St. Louis, Mo., in partnership with management, acquired LifeSpan Biosciences, Inc., on August 31, 2018. LSBio is a founder-led developer and distributor of antibodies and related reagents whose customer base is primarily the academic and pharmaceutical research markets.

LSBio, originally founded in 1995 as an immunohistochemistry services provider, today offers a broad range of antibodies, kits, proteins and other biological reagents. Its offerings include proprietary, value-added and third-party products, and researchers have long-relied on its expertise to fulfill their molecular pathology needs. As part of its growth strategy, the company plans to continue to expand its catalog of high-quality reagents, both through internal research and development and a targeted acquisition strategy.

Thompson Street Capital Partners invests in founder-led middle-market businesses in the healthcare and life sciences services, software and technology services, and business services and engineered products sectors. Founded in 2000, the firm has acquired more than 100 companies to date.